Previous Close | 44.28 |
Open | 43.86 |
Bid | 43.76 x 40000 |
Ask | 43.90 x 27000 |
Day's Range | 43.73 - 43.87 |
52 Week Range | 25.71 - 44.99 |
Volume | |
Avg. Volume | 39,768 |
Market Cap | 18.854B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.02 |
Earnings Date | Aug 08, 2024 |
Forward Dividend & Yield | 0.50 (1.12%) |
Ex-Dividend Date | May 03, 2024 |
1y Target Est | N/A |
MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicineSingle-dose 100 mg vial for intravenous use, approved for metastatic breast cancerLaunch expected to be near-term growth driver in US market Princeton, NJ, October 11, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has launched a generic paclitaxel formulation in the US, the first generic to its reference medicine to be approved by the US Food and Drug Admi
Read about Bausch + Lomb, Sandoz Group and more in the latest Market Talks covering the Health Care sector.